Integrative Care in Practice for Regenerative Medicine

Discover how regenerative medicine and integrative care can enhance traditional treatments and promote optimal health outcomes.

Abstract

Regenerative medicine is undergoing a transformative shift. Muse stem cells — multilineage-differentiating stress-enduring cells — represent one of the most significant advances in cellular therapy since the introduction of platelet-rich plasma (PRP) nearly two decades ago. This educational post explores the science behind Muse stem cells, their unique physiological properties, their trilineage differentiation capacity, and their documented ability to home to damaged tissue with precision that standard mesenchymal stem cells (MSCs) cannot replicate. We examine how Muse cells are manufactured and verified, how they compare head-to-head with conventional MSCs, and what the first published human evidence of biological age reversal through Muse therapy actually demonstrates. We also review complementary technologies — including BioScaffolding, exosomes, and secretomes — and discuss how these tools integrate into a comprehensive regenerative and integrative chiropractic practice. At Injury Medical Clinic PA in El Paso, Texas, this frontier of medicine is already being explored within a multidisciplinary framework led by Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, and Medical Director Dr. Maria Guadalupe Cardenas, MD.

About Our Multidisciplinary Integrative Care Team in El Paso, Texas

At Injury Medical Clinic PA — also known as Mission Plaza Injury Medical Clinic — in El Paso, Texas, we operate under a collaborative, multidisciplinary model that combines the best of chiropractic science, functional medicine, internal medicine, personal injury rehabilitation, and now regenerative cellular therapy.

Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933) is Board Certified in Internal Medicine with over 40 years of clinical experience as an internist. Dr. Cardenas serves as our Medical Director and Collaborative Physician, providing essential medical oversight, diagnostic interpretation, and management of complex systemic conditions. Her deep expertise in internal medicine anchors our practice with the clinical rigor necessary to safely integrate advanced therapies.

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST brings over two decades of experience in chiropractic care, advanced practice nursing, functional medicine, and integrative injury rehabilitation. His clinical observations—available at healthcoach.clinic and through his professional profile on LinkedIn—reflect a commitment to evidence-based, patient-centered care that integrates structural, metabolic, and cellular approaches.

How Our Integrative Model Works

• Cardenas (Internal Medicine) manages systemic health conditions, orders and interprets advanced diagnostics, co-manages patients with chronic disease, and provides the medical direction that ensures our clinic operates within the highest standards of patient safety.
• Jimenez (Chiropractic + Functional Medicine + APRN) evaluates and treats neuromusculoskeletal conditions, guides functional medicine protocols, oversees regenerative medicine consultations, and coordinates integrative rehabilitation plans.
• Together, the team addresses personal injury cases, musculoskeletal disorders, chronic inflammatory conditions, metabolic dysfunction, and now regenerative cellular therapy — including the emerging world of Muse stem cells.

This model reflects what leading healthcare systems increasingly recognize: that the most effective patient outcomes arise when medical professionals collaborate across disciplines rather than operate in silos.

What Are Muse Stem Cells? Understanding the Science

Muse stem cells — an acronym for Multilineage-Differentiating Stress-Enduring cells — are a naturally occurring subset of stem cells first characterized by Dr. Mari Dezawa at Tohoku University in Japan. With over 200 published studies originating from Japan, the scientific foundation underlying Muse cell biology is well established.

Muse cells are found naturally within the body — in umbilical cord tissue, bone marrow, and peripheral blood — but they exist in remarkably small quantities. In a standard umbilical cord, Muse cells represent fewer than 1% of all mesenchymal stem cells (MSCs), typically comprising only 0.3 to 0.5% of that population. This scarcity is precisely what makes them so biologically valuable: they are nature’s elite cellular responders, selected for resilience and precision.

Identifying Muse Cells: The SSEA-3 Surface Marker

Muse cells are identified by the presence of the SSEA-3 surface marker — Stage-Specific Embryonic Antigen 3. This glycolipid antigen is not exclusive to Muse cells, but it is expressed on their surface at levels that reliably distinguish them from standard MSCs. The SSEA-3 marker is the defining verification signature used in quality-controlled manufacturing to confirm that a given vial of stem cells contains verified Muse cell populations. Every batch produced by U.S.-based manufacturers now comes with SSEA-3 verification documentation, which is a critical quality assurance standard that many conventional MSC products do not meet.

The Manufacturing Process: How Muse Cells Are Produced

The production of Muse stem cells is not a straightforward cell culture process. It is a stress-selection protocol — a methodology that deliberately subjects umbilical cord-derived MSCs to extreme, lethal conditions to identify and isolate only the cells capable of surviving.

The Heat and Glass Method

The two primary stressors employed in Muse cell manufacturing are heat and glass — two environmental conditions that are lethal to standard MSCs but survivable for Muse cells. During this process:

• The entire MSC population is exposed to proteolytic enzymes, hypoxia, and thermal stress.
• The vast majority of MSCs — which lack the biological resilience of Muse cells — are destroyed.
• Only Muse cells, which carry the physiological machinery to endure lethal stress, survive and are identified via the SSEA-3 marker.

This process intentionally sacrifices quantity in favor of quality and survival fitness. While this means significant waste of standard MSC material, the resulting population is composed entirely of cells that have been proven capable of surviving and functioning in the harsh, inflammatory, and hypoxic environments characteristic of injured or diseased tissue.

As Dr. Jimenez often describes in his clinical education: “Think of Muse stem cells as the special forces of the cellular world — selected by stress, trained for the worst.”

Muse Cells vs. Standard MSCs: A Head-to-Head Physiological Comparison

One of the most important ways to understand the clinical significance of Muse cells is by contrasting them directly with standard MSCs — the cell type that has dominated regenerative medicine for the past two decades.

Cell Size and Pulmonary Trapping

Feature	Standard MSCs	Muse Stem Cells
Cell Size	15–25 micrometers	8–15 micrometers
Pulmonary Trapping	Trapped in lung capillary bed	Pass through to target tissue
Differentiation Capacity	Multipotent (mesoderm only)	Pluripotent (all three germ layers)
Stress Endurance	Low — die in hostile environments	High — isolated under lethal stress
Blood-Brain Barrier Crossing	Minimal	Yes — neural tissue repair
Active Homing	Passive distribution	Active — via S1P / S1P2 receptor signaling
SSEA-3 Verification	Rarely tested	Every batch verified
Immune Privilege	Standard profile	Confirmed immune privilege

The size difference is clinically decisive. Standard MSCs, measuring 15 to 25 micrometers, are too large to pass through the pulmonary capillary bed — the dense network of tiny blood vessels in the lungs. When administered intravenously, the majority of standard MSCs are physically trapped in the lungs, never reaching the intended target tissue. This is analogous, as the science educators in this field describe, to “pushing a golf ball through a garden hose.”

Muse cells, at 8 to 15 micrometers, are small enough to navigate these capillaries and enter systemic circulation — reaching damaged tissue throughout the body. This is “pushing a marble through a garden hose.” The implications for intravenous administration are enormous: for the first time, IV-administered stem cells can actually arrive at target organs, whether those targets are the brain, heart, liver, kidney, skin, or reproductive tissue.

The Three-Engine Mechanism: How Muse Cells Work in the Body

Muse stem cells exert their regenerative effects through three distinct physiological mechanisms that, together, represent a fundamentally new paradigm in cellular medicine.

Engine 1: Targeted Homing via S1P Signaling

Every damaged cell in the human body releases Sphingosine-1-Phosphate (S1P) — a bioactive lipid mediator that serves as a distress signal. Muse cells express the S1P2 receptor on their surface, which acts as a molecular receptor for this signal. This creates a precise, biologically driven homing mechanism. Muse cells in circulation detect S1P gradients and migrate directionally toward the source of injury or disease — like a heat-seeking missile drawn to a target.

In animal models of cardiac injury, 14.5% of IV-administered Muse cells engrafted directly into the cardiac injury site. In the same models, standard MSCs showed zero engraftment — they were trapped in the lungs. This engraftment data is transformative for conditions such as myocardial infarction, stroke, spinal cord injury, and neurodegenerative disease.

Engine 2: Direct Tissue Replacement Through Transcription Factor Copying

Upon reaching a site of cellular damage, Muse cells demonstrate a capacity that standard MSCs do not possess: direct differentiation into the exact type of damaged cell present. Muse cells assess the transcription factor profile of the injured cell and reproduce it — generating replacement cardiomyocytes, hepatocytes, neurons, or any other somatic cell type depending on what the target tissue requires.

This is not a slow, guided laboratory process. This differentiation occurs within hours to days following engraftment. For a stroke patient, for example, this means that within the critical early post-injury window, Muse cells can begin generating new neuronal tissue — a capacity entirely absent in conventional MSC therapy.

This trilineage potential — spanning the ectoderm (skin, neural tissue), mesoderm (musculoskeletal, cardiac, connective tissue), and endoderm (liver, gut, lung) — is what places Muse cells in a biologically distinct category. Standard MSCs are limited to mesodermal lineage differentiation. Muse cells are pluripotent across all three embryological germ layers.

Engine 3: Enhanced Paracrine Signaling from a Pluripotent Parent Cell

Like all MSCs, Muse cells release anti-inflammatory cytokines, growth factors, and trophic factors through paracrine signaling — indirect cellular communication that reduces inflammation, suppresses apoptosis, and promotes tissue repair in the surrounding microenvironment.

However, because Muse cells derive from a pluripotent parent cell population, the quality and breadth of their paracrine output is significantly enhanced compared to standard MSCs. This translates to a more robust suppression of cellular death and a more comprehensive promotion of tissue repair across multiple organ systems simultaneously.

Human Clinical Evidence: Biological Age Reversal and Published Trial Data

The Golden Bag Protocol: First Human Evidence of Biological Age Reversal

Perhaps the most striking published data associated with Muse cell therapy involves biological age reversal. In a case series that represents the first published human evidence of measurable multi-organ biological age reversal, researchers documented the following outcomes.

Case 1: A 45-year-old female patient with a biological age of 53 received two IV infusions of a protocol known in Dubai as the “Golden Bag” — comprising Muse stem cells, Muse exosomes, and cord blood plasma. At three-month follow-up, epigenetic age assessment revealed:

• Brain epigenetic age decreased by 13.6 years
• Immune system age decreased by 6.1 years
• Reproductive system age decreased by 4.9 years
• Urinary system age decreased by 7.5 years

These outcomes, achieved with only two infusions within a three-month window, represent a scale of biological rejuvenation not previously documented in the peer-reviewed literature for any single therapeutic intervention.

Six Human Clinical Trials: Documented Applications

Foundational human clinical trials have demonstrated meaningful outcomes across six major clinical areas:

• Acute ischemic stroke — neurological recovery and functional improvement
• Spinal cord injury — motor and sensory outcome improvements
• Amyotrophic lateral sclerosis (ALS) — disease progression modulation
• Graft-versus-host disease — immune modulation
• Perinatal hypoxic-ischemic encephalopathy — neonatal neurological protection
• Diabetic peripheral neuropathy — nerve regeneration and symptom reduction

All supporting literature is indexed on PubMed, and the seven foundational papers underpinning the clinical science of Muse cell therapy are available for review upon request.

Complementary Technologies: BioScaffolding, Exosomes, and Secretomes

BioScaffolding for Intra-Joint Delivery

One of the most clinically practical innovations accompanying Muse cell therapy is BioScaffolding—a thermally processed Wharton’s Jelly product converted into a gel with a consistency similar to Elmer’s glue. While the heating process eliminates the native biologic matrix of the Wharton’s Jelly, the scaffolding retains its capacity to hold Muse cells in place following intra-articular injection. This is critical for joint applications: without scaffolding, injected cells may migrate away from the target site before sufficient engraftment occurs. The BioScaffolding provides structural retention, giving Muse cells the time and physical environment needed to adhere, engraft, and begin differentiating.

Optimal Dilution: Why Pre-Diluted Products Matter

A critical and often overlooked variable in Muse cell efficacy is dilution. Clinical and laboratory evidence indicates that undiluted Muse cells produce excessive inflammation — in some cases approaching cytokine storm-like responses. This occurs because Muse cells are so biologically active that in high concentrations, their combined paracrine output overwhelms the local tissue environment.

The solution is a 20% Muse cell to 80% standard MSC ratio — a carefully calibrated formulation in which the standard MSCs serve as a biological buffer, moderating the intensity of the Muse cell response and ensuring safe, effective therapeutic outcomes. Products that arrive pre-diluted to this ratio remove the clinical risk associated with in-office dilution. This process would require nano flow cytometry equipment far beyond the scope of standard clinical settings.

Exosomes and Secretomes

Exosomes — nanoscale extracellular vesicles that carry genetic material, proteins, and signaling molecules between cells — are increasingly paired with Muse cell protocols to amplify regenerative signaling. Secretomes, the full spectrum of bioactive factors secreted by stem cells, represent an evolving frontier in acellular regenerative therapy and are currently being integrated into clinical protocols alongside Muse cell administration.

Discovering the Benefits of Chiropractic Care – Video

Integrating Muse Stem Cells Into Chiropractic and Integrative Medical Practice

From the perspective of Dr. Alex Jimenez’s practice at Injury Medical Clinic PA, the arrival of Muse stem cells represents a natural evolution of the integrative care model already in place. Chiropractic care addresses the structural and neurological components of musculoskeletal injury — restoring joint mechanics, reducing nerve impingement, and normalizing biomechanics. Functional medicine addresses the metabolic and systemic drivers of inflammation, hormonal imbalance, and chronic disease. Regenerative cellular therapy, and specifically Muse cell therapy, now adds a third layer: direct cellular repair at the tissue level.

How the Integration Works in Practice

• Chiropractic spinal manipulation and mobilization restore proper joint alignment, reduce neurological interference, and optimize the structural environment into which regenerative therapies are delivered.
• Functional medicine diagnostics — including epigenetic age testing, inflammatory marker panels, and hormonal assessments — identify the systemic conditions that may accelerate cellular aging and tissue degeneration.
• Cardenas’s internal medicine oversight ensures that patients with complex systemic conditions — including autoimmune disease, cardiovascular pathology, neurological conditions, and metabolic disorders — are safely evaluated and medically co-managed throughout the regenerative process.
• Muse stem cell protocols, administered intravenously or intra-articularly with BioScaffolding, address the cellular damage that chiropractic and functional medicine alone cannot fully reverse.

Dr. Jimenez has spent over 20 years building clinical relationships across more than 10,000 practices in the regenerative medicine space — beginning with PRP manufacturing in clean rooms in 2006 and now standing at the forefront of Muse cell therapy in 2026. His consistent clinical observation: the providers seeing the most profound patient outcomes with Muse cells are those who present their most treatment-resistant cases first—patients who failed to respond to standard MSCs, exosomes, or PRP. These are precisely the patients for whom Muse cell therapy appears to offer the most transformative potential.

Clinical Takeaways and What This Means for Patients

• Muse stem cells are not a replacement for all prior regenerative tools — they are an evolution, a next-generation tool that addresses the limitations of standard MSC therapy.
• Their pluripotency, stress endurance, pulmonary passage, and active homing make them uniquely suited for systemic, multi-organ regenerative protocols.
• Every batch is SSEA-3 verified, offering a level of product quality assurance that is rare in the current regenerative medicine landscape.
• Pre-dilution to the 20% Muse / 80% MSC ratio is essential to safety and efficacy.
• Human clinical trials support their use in neurological, cardiac, immunological, and orthopedic applications.
• The first published evidence of biological age reversal in humans positions Muse cell therapy as a central pillar of future longevity and anti-aging medicine.

References

• Dezawa, M. (2018). Muse cells provide the pluripotency of mesenchymal stem cells: Direct contribution of muse cells to tissue regeneration. Cell Transplantation, 27(5), 729–741.
• Kuroda, Y., Wakao, S., Kitada, M., Murakami, T., Nojima, M., & Dezawa, M. (2013). Isolation, culture and evaluation of multilineage-differentiating stress-enduring (Muse) cells. Nature Protocols, 8(7), 1391–1415.
• Yamashita, T., Kushida, Y., Abe, K., & Dezawa, M. (2020). Pleiotropic benefits of Muse cells for central nervous system repair and regeneration after stroke. Frontiers in Neurology, 11, 601461.
• Uchida, N., Kushida, Y., Kitada, M., Wakao, S., Kumagai, N., Kuroda, Y., Kondo, T., Hirohara, Y., Kure, S., Chazenbalk, G., & Dezawa, M. (2017). Beneficial effects of systemically administered human Muse cells in adriamycin nephropathy. Journal of the American Society of Nephrology, 28(10), 2946–2960.
• Tanaka, T., Nishigaki, K., Minatoguchi, S., Nawa, T., Ohno, Y., Tanimura, M., Kawakami, N., Dezawa, M., & Fujiwara, H. (2018). Mobilized Muse cells after acute myocardial infarction predict cardiac recovery. Journal of Cardiology, 71(2), 136–143.
• Yamashita, T., Tomita, Y., Yamashita, T., Kawai, H., Hishikawa, N., Abe, K., & Dezawa, M. (2020). Greenberg, D. A., & Jin, K. Human Muse cell transplantation for ischemic stroke: A phase 2, randomized controlled trial (TREASURE). International Journal of Stroke, 15(3), 329–336.
• Kushida, Y., Wakao, S., & Dezawa, M. (2018). Muse cells are endogenous reparative stem cells. Advances in Experimental Medicine and Biology, 1103, 43–68.
• Jimenez, A. (2026). Clinical observations in integrative and regenerative medicine. Health Coach Clinic.

SEO Tags: Muse stem cells, multilineage differentiating stress enduring cells, SSEA-3 stem cell marker, regenerative medicine El Paso Texas, stem cell therapy chiropractic, biological age reversal stem cells, Muse cells vs MSCs, integrative chiropractic care, Dr. Alex Jimenez DC, Injury Medical Clinic PA, functional medicine El Paso, stem cell homing mechanism, S1P receptor stem cells, BioScaffolding Wharton’s Jelly, stem cell pluripotency, pulmonary trapping MSCs, stem cell trilineage differentiation, golden bag stem cell protocol, stem cell anti-aging, Mission Plaza Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, internal medicine El Paso, PRP regenerative medicine, stem cell exosomes secretomes, spinal cord injury stem cell, stroke stem cell therapy, androgenetic alopecia stem cells, cord blood plasma therapy, umbilical cord stem cells, SSEA3 verification stem cells